Basic Science for the Clinician 34

Detection of lymphangiogenesis by near-infrared fluorescence imaging and responses to VEGF-C during healing in a mouse full-dermis thickness wound model

Noninvasive, longitudinal near-infrared fluorescence (NIRF) imaging was used to detect and quantify lymphangiogenesis following a full-dermis thickness incision in the presence and absence of locally administered vascular endothelial growth factor-C (VEGF-C), a well-known regulator of lymphangiogenesis. Peripheral cytokines/chemokines were also measured in treated and sham-injected animals. Lymphangiogenesis was detected via NIRF imaging by day 7-8 and confirmed by intravital microscopy, while angiogenesis was observed by day 2-3 postincision (PI). All lymph vessel parameters quantified were significantly greater on wounded vs. nonwounded sides of mice. Lymph vessel parameters appeared larger on wounded sides of VEGF-C- relative to NaCl-treated mice, although differences were not significant. Interleukin-1α and interleukin-22 were significantly elevated at day 7 PI relative to respective preincision levels in VEGF-C-treated mice, and decreased by day 21 PI to levels nearing those measured preincision. For the majority of cytokines/chemokines measured, mean responses were significantly greater in VEGF-C- vs. NaCl-treated animals. Local VEGF-C administration may stimulate lymphangiogenesis during tissue repair and regeneration via mediating systemic cytokine/chemokine levels. NIRF imaging can be utilized to detect lymphangiogenesis during wound healing, and offers a promising platform to complement current methods for monitoring wound status and studying the effects of growth factors on healing.

Elevated systemic interleukin-18 in multiple injured patients is not related to clinical outcome

Interleukin-18 (IL-18) is a pleiotropic proinflammatory cytokine with the ability to induce interferon-gamma production in T-helper cells type 1 and natural killer cells. To investigate the role of IL-18 after severe trauma we measured plasma levels of IL-18 in 229 multiple injured patients [mean age of 39 +/- 16 (range 11-81) years, injury severity score (ISS) of 31 +/- 10 (range 16-66) points; 55 women and 174 men] and correlated these with demographics, clinical course, and routine laboratory parameters. IL-18 plasma levels were significantly increased in polytraumatized patients compared to healthy donors (p < 0.001). Survivors presented significantly (p < 0.05) higher IL-18 plasma median values (n = 193, median 98 pg/mL) compared to nonsurvivors (n = 36, median 63 pg/mL). Patients >60 years old (n = 35) had significantly lower plasma levels of IL-18 (median 45 pg/mL) compared to younger ones (n = 194, median 92 pg/mL). In the subgroup of nonsurvivors (n = 12) elderly patients had the lowest plasma levels of IL-18 (median 45 pg/mL). Patients with an ISS >25 had significant higher IL-18 plasma levels compared to the group with an ISS <or=25 (p < 0.001). Our data demonstrate elevated plasma levels of IL-18 after severe trauma.

Basic science for the clinician 45: CD4+ T-cell subsets of probable clinical consequence

I have often said "blessed be the splitters, for they shall inherit the earth." By that I mean that it is only by studying carefully culled populations, approaching, but never quite reaching, homogeneity that we can ever gain real insights into rheumatologic diseases. Differentiating tuberculous from gouty from rheumatoid arthritis was a good start, and when Moll and Wright identified the seronegative spondyloarthropathies, we were on our way to establishing "splitters" as leaders. Predictably, once T cells were identified as different from B cells, the floodgates opened. Subsets galore were described, with more isolated populations in the T-cell family, but we are now finding heterogeneity in B-cell populations, as well, which has been discussed in a previous article in this series. But as for T cells... well, it has not been smooth sailing. I initially trained in a laboratory that was firmly committed to the proposition that there were within the CD8 population not only cytotoxic cells but also "suppressor cells." Problem is, no one could ever isolate the little buggers, and so the idea of a suppressor or regulatory subpopulation of CD8+ T cells went the way of the Edsel. As noted in a previous article in this series, T regulatory cells were finally identified but not within the CD8+ population. And there are other regulatory subsets within both CD4+ and CD8+ T-cells populations and even new effector and memory populations that can be identified by their surface markers and functions. It is high time to review some of them; some of these populations may be involved in the immunopathogenesis of our diseases and undoubtedly will shortly be targets of immunotherapeutics. Although previous articles in this series discussed some of these subsets, I thought expanding on what is known about another recently described subset and putting them all together in one review might be helpful.

Interleukin 18 and periodontal disease

Cytokines are of major importance in periodontal disease progression. It is generally agreed that control of the Th1/Th2 balance is central to the immunoregulation of periodontal disease. There is increasing evidence in humans that the stable periodontal lesion is mediated by Th1 cells, while the progressive lesion sees a shift toward Th2 cells. Equally, there is conflicting evidence, mainly in animal models, that bone loss is mediated by Th1 responses, and that Th2 responses are protective. In the presence of IL-12, IL-18 induces Th1 responses while, in the absence of IL-12, it promotes Th2 responses. It is clear, therefore, that since IL-18 has the ability to induce either Th1 or Th2 differentiation, it becomes important to consider its role in periodontal disease. This review endeavors to give an overview of this cytokine and its relevance for periodontal disease.